Tags

Type your tag names separated by a space and hit enter

Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus.
J Rheumatol 2000; 27(6):1403-7JR

Abstract

OBJECTIVE

To clarify the clinical significance of anticentromere antibodies (ACA) in patients with systemic lupus erythematosus (SLE).

METHODS

Two hundred sixteen patients with SLE who were treated in our department were surveyed cross sectionally for the presence of ACA using indirect immunofluorescence on HEp-2 cell lines. ACA were identified by their discrete speckled pattern. Antibodies to the major centromere protein, CENP-B, were also studied with ELISA. Serial determinations of anti-CENP-B were carried out using stored serum samples, if available.

RESULTS

ACA were recognized in 12 (5.6%) patients with SLE. All patients were receiving steroid therapy, with a mean dose of prednisolone of 14.4 mg/day. These patients also tested positive for anti-CENP-B with high titers despite the low serological disease activity in most. Three or more CREST features were observed in 2 patients and 2 others had no such features. Both patients without CREST features had a relatively short disease duration. The age at onset of SLE was significantly higher and Raynaud's phenomenon was more frequent in patients with ACA than in patients without ACA. In 8 of 10 patients tested, retrospective analysis using stored sera revealed no consistent change in anti-CENP-B titers over time.

CONCLUSION

The presence of ACA in patients with SLE is apparently more frequent than previously believed. Patients with SLE with ACA may be a distinct subgroup. A longterm followup is warranted to fully determine the clinical significance of ACA in patients with SLE.

Authors+Show Affiliations

Department of Medicine II, Niigata University School of Medicine, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

10852261

Citation

Nakano, M, et al. "Clinical Significance of Anticentromere Antibodies in Patients With Systemic Lupus Erythematosus." The Journal of Rheumatology, vol. 27, no. 6, 2000, pp. 1403-7.
Nakano M, Ohuchi Y, Hasegawa H, et al. Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus. J Rheumatol. 2000;27(6):1403-7.
Nakano, M., Ohuchi, Y., Hasegawa, H., Kuroda, T., Ito, S., & Gejyo, F. (2000). Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus. The Journal of Rheumatology, 27(6), pp. 1403-7.
Nakano M, et al. Clinical Significance of Anticentromere Antibodies in Patients With Systemic Lupus Erythematosus. J Rheumatol. 2000;27(6):1403-7. PubMed PMID: 10852261.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus. AU - Nakano,M, AU - Ohuchi,Y, AU - Hasegawa,H, AU - Kuroda,T, AU - Ito,S, AU - Gejyo,F, PY - 2000/6/14/pubmed PY - 2000/10/14/medline PY - 2000/6/14/entrez SP - 1403 EP - 7 JF - The Journal of rheumatology JO - J. Rheumatol. VL - 27 IS - 6 N2 - OBJECTIVE: To clarify the clinical significance of anticentromere antibodies (ACA) in patients with systemic lupus erythematosus (SLE). METHODS: Two hundred sixteen patients with SLE who were treated in our department were surveyed cross sectionally for the presence of ACA using indirect immunofluorescence on HEp-2 cell lines. ACA were identified by their discrete speckled pattern. Antibodies to the major centromere protein, CENP-B, were also studied with ELISA. Serial determinations of anti-CENP-B were carried out using stored serum samples, if available. RESULTS: ACA were recognized in 12 (5.6%) patients with SLE. All patients were receiving steroid therapy, with a mean dose of prednisolone of 14.4 mg/day. These patients also tested positive for anti-CENP-B with high titers despite the low serological disease activity in most. Three or more CREST features were observed in 2 patients and 2 others had no such features. Both patients without CREST features had a relatively short disease duration. The age at onset of SLE was significantly higher and Raynaud's phenomenon was more frequent in patients with ACA than in patients without ACA. In 8 of 10 patients tested, retrospective analysis using stored sera revealed no consistent change in anti-CENP-B titers over time. CONCLUSION: The presence of ACA in patients with SLE is apparently more frequent than previously believed. Patients with SLE with ACA may be a distinct subgroup. A longterm followup is warranted to fully determine the clinical significance of ACA in patients with SLE. SN - 0315-162X UR - https://www.unboundmedicine.com/medline/citation/10852261/Clinical_significance_of_anticentromere_antibodies_in_patients_with_systemic_lupus_erythematosus_ L2 - http://www.diseaseinfosearch.org/result/9373 DB - PRIME DP - Unbound Medicine ER -